Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

As the industry looks toward 2026, data center architects and system designers face a convergence of pressures that make storage design more critical than ever. AI workloads continue to drive ...

Survey of over 2,000 Java professionals also reveals: 92% are concerned about Oracle Java pricing and 81% are migrating all or some of their Oracle Java to OpenJDK as cost concerns mount SUNNYVALE, ...

If AI were a bubble, Big Tech wouldn’t be pouring trillions into compute — 2026 will be defined by who controls inference power. There’s a lot of talk about the AI surge being a bubble that’s about to ...

Broadcom is proving to be a key beneficiary in the AI networking market, with around $20 billion of non-accelerator AI backlog. Coherent is also benefiting from the ongoing AI networking upgrade cycle ...

At a recent all-hands meeting, Google's head of AI infrastructure, Amin Vahdat, said the company has to race to build out compute capacity in order to meet demand. Vahdat said Google bolsters its AI ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Space has always been a premium in the datacenter, but the heat is on – quite literally – to drive up the density of GPU and XPU compute not just because real estate is expensive, but because latency ...

Acurast raised $11 million to launch a smartphone-based confidential compute network that claims tamper-resistant execution on consumer phones. Smartphone-based decentralized confidential compute ...

The fight for AI’s future now centers on compute. Whoever controls the chips will control the next decade of innovation. When AI startups, research labs and even Fortune 500 companies compete for the ...

NEW ORLEANS, LA—A single subcutaneous injection of a novel, small-molecule glycoprotein IIb/IIIa inhibitor administered at first medical contact in patients with suspected STEMI improves the patency ...